Laboratory of Chemistry and Cell Biology, The Rockefeller University, New York, New York 10065, USA.
J Am Chem Soc. 2011 Aug 17;133(32):12386-9. doi: 10.1021/ja204561q. Epub 2011 Jul 21.
It is difficult to determine a chemical inhibitor's binding site in multiprotein mixtures, particularly when high-resolution structural studies are not straightforward. Building upon previous research involving photo-cross-linking and the use of mixtures of stable isotopes, we report a method, Stable Isotope Labeled Inhibitors for Cross-linking (SILIC), for mapping a small molecule inhibitor's binding site in its target protein. In SILIC, structure-activity relationship data is used to design inhibitor analogues that incorporate a photo-cross-linking group along with either natural or 'heavy' stable isotopes. An equimolar mixture of these inhibitor analogues is cross-linked to the target protein to yield a robust signature for identifying inhibitor-modified peptide fragments in complex mass spectrometry data. As a proof of concept, we applied this approach to an ATP-competitive inhibitor of kinesin-5, a widely conserved motor protein required for cell division and an anticancer drug target. This analysis, along with mutagenesis studies, suggests that the inhibitor binds at an allosteric site in the motor protein.
在多蛋白混合物中确定化学抑制剂的结合位点很困难,特别是当高分辨率结构研究不直接时。在涉及光交联和使用稳定同位素混合物的先前研究的基础上,我们报告了一种方法,即用于交联的稳定同位素标记抑制剂(SILIC),用于绘制小分子抑制剂在其靶蛋白中的结合位点。在 SILIC 中,结构-活性关系数据用于设计包含光交联基团以及天然或“重”稳定同位素的抑制剂类似物。将这些抑制剂类似物的等摩尔混合物交联到靶蛋白上,以在复杂的质谱数据中产生用于鉴定抑制剂修饰肽片段的稳健特征。作为概念验证,我们将这种方法应用于一种针对驱动蛋白-5 的 ATP 竞争性抑制剂,驱动蛋白-5 是一种广泛保守的马达蛋白,是细胞分裂所必需的,也是抗癌药物的靶标。这项分析以及突变研究表明,抑制剂结合在马达蛋白的变构位点上。